Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.
Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. We demonstrate the significance of genetic-based risk classification that clearly segregate patients into low (no genetic abnormalities or only t(11;14)), intermediate (any one of the genetic abnormalities other than t(11;14)) and high-risk groups (any two or more of the genetic abnormalities other than t(11;14)). High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies.
Chang
H
H
Department of Laboratory Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada. hong.chang@uhn.on.ca
Qi
X Y
XY
Samiee
S
S
Yi
Q-L
QL
Chen
C
C
Trudel
S
S
Mikhael
J
J
Reece
D
D
Stewart
A K
AK
D000328:Adult; D000368:Aged; D002872:Chromosome Deletion; D002877:Chromosomes, Human / Q000235:genetics*; D000529:Complementary Therapies; D005260:Female; D017353:Gene Deletion; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000379:methods; D014178:Translocation, Genetic; D014182:Transplantation, Autologous; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D016159:Tumor Suppressor Protein p53